Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder

GI Papakostas, DV Iosifescu, T Petersen… - Journal of clinical …, 2004 - journals.lww.com
A growing number of studies report that patients with depression may differ in terms of their
cholesterol levels from nondepressed psychiatric patients or normal controls. 1 In a previous …

Noradrenergic adverse effects due to combined treatment with reboxetine and triiodothyronine

R Cooper-Kazaz, A Cohen, B Lerer - Journal of clinical …, 2010 - journals.lww.com
DISCUSSION Cholesterol levels, as assessed before randomization, were negatively
related to physical aggression during the 4-week baseline period. There was also a …

Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder

SB Sonawalla, GI Papakostas, TJ Petersen, AS Yeung… - Psychosomatics, 2002 - Elsevier
Previous studies have suggested that patients with major depressive disorder may have
lower cholesterol levels compared to healthy controls. The purpose of this study was to …

Baseline lipid levels and acute treatment response to paroxetine and tianeptine in depressed women

D Mück-Seler, M Sagud, A Mihaljevi-Peles… - Journal of clinical …, 2011 - journals.lww.com
To the Editors: Leukopenia and neutropenia may be associated with a range of
antipsychotics, mood stabilizers, and selective serotonin reuptake inhibitors, especially …

Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy

DJ Brunswick, JD Amsterdam, J Fawcett… - Journal of clinical …, 2001 - journals.lww.com
Among the selective serotonin reuptake inhibitors, fluoxetine has the longest elimination half-
life (t 1/2). It has been suggested that the pharmacokinetic profile of fluoxetine may change …

Antidepressant drug prescribing patterns to outpatients of an Italian local health authority during the years 1998 to 2008

P Deambrosis, A Chinellato, G Terrazzani… - Journal of clinical …, 2010 - journals.lww.com
DISCUSSION Cholesterol levels, as assessed before randomization, were negatively
related to physical aggression during the 4-week baseline period. There was also a …

Effects of adding cognitive therapy to fluoxetine dose increase on risk of relapse and residual depressive symptoms in continuation treatment of major depressive …

RH Perlis, AA Nierenberg, JE Alpert… - Journal of Clinical …, 2002 - journals.lww.com
Patients with major depressive disorder remain at risk for relapse following remission and
often continue to experience subthreshold symptoms. This study compared the rate of …

Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression

CM Miner, EB Brown, JS Gonzales… - Journal of Clinical …, 2002 - psychiatrist.com
Background: Major depressive disorder is frequently a chronic, recurrent condition
necessitating maintenance treatment. For some patients, compliance with daily …

The effects of fluoxetine versus nortriptyline on body weight in depression

KA Gendall, PR Joyce, RT Mulder… - Journal of Clinical …, 2000 - journals.lww.com
Although tricyclic antidepressants produce initial remission rates similar to those for
selective serotonin reuptake inhibitors, 1 distinctions between these groups of medications …

Do serum lipids predict response to clozapine treatment?

RM Procyshyn, WG Honer, AM Barr - Journal of Psychiatry and …, 2009 - jpn.ca
RP was a 26-year old man with a 9-year history of schizophrenia. 1 Refractory to previous
trials of antipsychotics, he was prescribed clozapine. After 3 weeks of 225 mg/d on …